Furthermore, compliance

to study drug was not quantified;

Furthermore, compliance

to study drug was not quantified; rather, adherence was assessed via patient self-report. Also, patients who were reportedly noncompliant for at least 3 months were considered discontinued. However, many patients who were considered to be compliant may have had smaller gaps in their therapy, which may have impacted their fracture Talazoparib datasheet risk. Therefore, it was not possible to assess this factor in this study. The median duration of 23 months of TPTD treatment in this observational study may be higher than the typical community experience. This may be attributed to the types of practices that participated in the DANCE study. Most of the investigators were bone specialists with primarily a referral practice. Patient motivation and physician attitudes about treating osteoporosis with TPTD LDK378 concentration may be different from a primary care practice and could influence patient persistence. It is possible that the higher incidence of fracture during the first 6 months of the study was due to a history of a recent fracture. However, many patients had a history of fracture that predated initiation of TPTD by a considerable length of time. The reduction in fracture incidence during the 24-month cessation phase remained significant compared to the reference (>0 to ≤6 months of treatment). During the cessation phase, physicians were asked

to treat their patients per their standard of care after a course of TPTD. Most patients were placed on an antiresorptive drug (55.5 % had an antiresorptive drug documented during cessation phase); therefore, these reductions cannot be solely attributed to the previous treatment with TPTD. However, it is reassuring that with standard care, which usually includes use of an antiresorptive

drug after treatment with TPTD, 4-Aminobutyrate aminotransferase the incidence of NVFX remained significantly lower than the baseline reference period. Nonvertebral fracture sites recorded included the ankle, clavicle, distal forearm, fingers, foot, hand, hip, humerus, knee, leg, pelvis, rib, shoulder, skull, sternum, and toes. While most clinical trials do not include sites such as finger, toes, and skull, the authors feel comfortable including all NVFX in the analysis. All NVFX sites were included in both the reference time period and all subsequent time periods. The biologic effect of TPTD is not likely to alter the incidence of fractures of fingers, toes, and skull significantly. Therefore, the likelihood of these fracture sites significantly altering the overall incidence is low. Unfortunately, because of the way the data were collected, it was not possible to separate out the toe or finger fractures. A post hoc analysis of the fracture data with exclusion of hand/finger, foot/toe, and other fractures gave very similar results to “all NVFX” reported in this analysis.

Comments are closed.